Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

Phase 4 Withdrawn Baylor Research Institute

NaSingle-groupOpen-labelTreatment

Summary

Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

Timeline

Start: 2019-12-23
Primary completion: 2021-09-24
Completion: 2021-10-01

Outcome

Outcome not reported

Stopped: “Difficult to find eligible patients willing to participate.”

Publications

Kao CC, Hanania NA, Parulekar AD. The impact of fungal allergic sensitization on asthma. Curr Opin Pulm Med. 2021 Jan;27(1):3-8. doi: 10.1097/MCP.0000000000000740.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Benralizumab	Monoclonal antibody	30 mg/ml	Subcutaneous